Management of active tuberculosis in adults with HIV

Graeme Meintjes, James C.M. Brust, James Nuttall, Gary Maartens

Research output: Contribution to journalReview article

Abstract

Every year, about 1 million people living with HIV worldwide develop tuberculosis. Although the drug regimens used to treat tuberculosis in these patients are the same as those used in HIV-negative patients, cotreatment of tuberculosis with antiretroviral therapy involves challenges including the optimal timing of antiretroviral initiation, drug-drug interactions, drug tolerability, and the prevention and treatment of tuberculosis-associated immune reconstitution syndrome. Furthermore, mortality is high in people with HIV who are diagnosed with tuberculosis during a hospital admission, and in those with tuberculous meningitis. Studies in this field have better characterised these challenges and informed optimal management and guideline revisions. In patients with tuberculosis, antiretroviral therapy improves survival, is well tolerated, and can be adjusted to manage drug-drug interactions with rifampicin. Prednisone is effective in both preventing and treating the paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.

Original languageEnglish (US)
Pages (from-to)e463-e474
JournalThe Lancet HIV
Volume6
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Tuberculosis
HIV
Immune Reconstitution Inflammatory Syndrome
Drug Interactions
Pharmaceutical Preparations
Meningeal Tuberculosis
Rifampin
Prednisone
Therapeutics
Guidelines
Survival
Mortality

ASJC Scopus subject areas

  • Epidemiology
  • Immunology
  • Infectious Diseases
  • Virology

Cite this

Management of active tuberculosis in adults with HIV. / Meintjes, Graeme; Brust, James C.M.; Nuttall, James; Maartens, Gary.

In: The Lancet HIV, Vol. 6, No. 7, 01.07.2019, p. e463-e474.

Research output: Contribution to journalReview article

Meintjes, Graeme ; Brust, James C.M. ; Nuttall, James ; Maartens, Gary. / Management of active tuberculosis in adults with HIV. In: The Lancet HIV. 2019 ; Vol. 6, No. 7. pp. e463-e474.
@article{1366725298ce437cb0b7dfb67e53dc2b,
title = "Management of active tuberculosis in adults with HIV",
abstract = "Every year, about 1 million people living with HIV worldwide develop tuberculosis. Although the drug regimens used to treat tuberculosis in these patients are the same as those used in HIV-negative patients, cotreatment of tuberculosis with antiretroviral therapy involves challenges including the optimal timing of antiretroviral initiation, drug-drug interactions, drug tolerability, and the prevention and treatment of tuberculosis-associated immune reconstitution syndrome. Furthermore, mortality is high in people with HIV who are diagnosed with tuberculosis during a hospital admission, and in those with tuberculous meningitis. Studies in this field have better characterised these challenges and informed optimal management and guideline revisions. In patients with tuberculosis, antiretroviral therapy improves survival, is well tolerated, and can be adjusted to manage drug-drug interactions with rifampicin. Prednisone is effective in both preventing and treating the paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.",
author = "Graeme Meintjes and Brust, {James C.M.} and James Nuttall and Gary Maartens",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/S2352-3018(19)30154-7",
language = "English (US)",
volume = "6",
pages = "e463--e474",
journal = "The Lancet HIV",
issn = "2352-3018",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Management of active tuberculosis in adults with HIV

AU - Meintjes, Graeme

AU - Brust, James C.M.

AU - Nuttall, James

AU - Maartens, Gary

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Every year, about 1 million people living with HIV worldwide develop tuberculosis. Although the drug regimens used to treat tuberculosis in these patients are the same as those used in HIV-negative patients, cotreatment of tuberculosis with antiretroviral therapy involves challenges including the optimal timing of antiretroviral initiation, drug-drug interactions, drug tolerability, and the prevention and treatment of tuberculosis-associated immune reconstitution syndrome. Furthermore, mortality is high in people with HIV who are diagnosed with tuberculosis during a hospital admission, and in those with tuberculous meningitis. Studies in this field have better characterised these challenges and informed optimal management and guideline revisions. In patients with tuberculosis, antiretroviral therapy improves survival, is well tolerated, and can be adjusted to manage drug-drug interactions with rifampicin. Prednisone is effective in both preventing and treating the paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.

AB - Every year, about 1 million people living with HIV worldwide develop tuberculosis. Although the drug regimens used to treat tuberculosis in these patients are the same as those used in HIV-negative patients, cotreatment of tuberculosis with antiretroviral therapy involves challenges including the optimal timing of antiretroviral initiation, drug-drug interactions, drug tolerability, and the prevention and treatment of tuberculosis-associated immune reconstitution syndrome. Furthermore, mortality is high in people with HIV who are diagnosed with tuberculosis during a hospital admission, and in those with tuberculous meningitis. Studies in this field have better characterised these challenges and informed optimal management and guideline revisions. In patients with tuberculosis, antiretroviral therapy improves survival, is well tolerated, and can be adjusted to manage drug-drug interactions with rifampicin. Prednisone is effective in both preventing and treating the paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.

UR - http://www.scopus.com/inward/record.url?scp=85068040930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068040930&partnerID=8YFLogxK

U2 - 10.1016/S2352-3018(19)30154-7

DO - 10.1016/S2352-3018(19)30154-7

M3 - Review article

C2 - 31272663

AN - SCOPUS:85068040930

VL - 6

SP - e463-e474

JO - The Lancet HIV

JF - The Lancet HIV

SN - 2352-3018

IS - 7

ER -